Six of the MPN cases with CCN2 overexpression contained/showed a JAK2 V617F mutation/clone with a variant allele frequency (VAF) ranging from 5.8 to 79%, not significantly correlating with the CCN2 score (p = 0.090). This evidence concerns the gene JAK2 and myeloproliferative neoplasm.